This medical study explores the drug CBL0137 to treat tough-to-cure cancers called solid tumors, including those in the brain (CNS tumors) and a type of cancer called lymphoma. This study looks at how much of the drug can be safely given and if it helps slow down or stop cancer growth. CBL0137 works by blocking signals in cells that help them grow and survive, which might help kill cancer cells.
- Study involves receiving the drug through an IV on specific days over a 21-day cycle, for up to 17 cycles.
- Participants must be between 12 months and 30 years old and have certain types of cancer.
- Regular follow-ups scheduled up to 60 months after treatment ends.
In this study, doctors aim to find the best dose while checking for side effects and benefits. This study might be right for patients who have tried other treatments without success. Participants will undergo various tests to check their health and monitor any changes in their condition. If you're considering this study, talk to your doctor to see if it's a good fit for you.